CHRISTOPH LENGAUER

Christoph Lengauer stands as a key Partner at Third Rock Ventures, a leading venture capital firm dedicated to building transformative life science companies. In his role, Dr. Lengauer is instrumental in the firm's unique company creation model, working closely with scientific founders to translate cutting-edge research into innovative therapeutic solutions. His expertise spans the entire spectrum of biotech development, from initial concept to clinical execution, making him a vital force in the venture capital landscape.

Dr. Lengauer's investment focus at Third Rock Ventures is primarily centered on areas of significant unmet medical need. He is particularly passionate about oncology, immunology, rare diseases, and neurodegenerative disorders. He seeks out opportunities where groundbreaking science can lead to the development of precision medicines and novel therapeutic modalities that have the potential to profoundly impact patient lives. His strategic vision helps guide the formation and growth of companies poised to disrupt traditional approaches to disease treatment.

Before joining Third Rock Ventures, Christoph Lengauer built an impressive career marked by significant leadership roles in both biotech and large pharmaceutical companies. He served as Chief Medical Officer at Blueprint Medicines, a Third Rock Ventures portfolio company that successfully developed targeted therapies for various cancers. Prior to Blueprint, he held the position of Vice President, Global Head of Oncology Translational Medicine at Novartis, where he oversaw critical aspects of early-stage oncology drug development. His extensive experience also includes leadership roles at Sanofi-Aventis, where he was Vice President, Head of Oncology Development, contributing to the advancement of numerous cancer therapies.

Academically, Dr. Lengauer earned his medical degree from the University of Vienna, Austria, and completed postdoctoral work at Harvard Medical School. He is board-certified in Internal Medicine and Hematology/Oncology, providing him with a deep clinical understanding that informs his investment decisions. This robust background in both clinical practice and drug development uniquely positions him to identify and cultivate promising scientific endeavors.

Throughout his tenure, Christoph Lengauer has been deeply involved in the creation and success of several notable companies. Beyond Blueprint Medicines, he has played a critical role in the development of firms such as Revolution Medicines, Celsius Therapeutics, Cedilla Therapeutics, and Flare Therapeutics. These companies exemplify his commitment to fostering innovation and bringing forward new treatments that address complex diseases. His contributions underscore his dedication to advancing the field of life sciences and delivering meaningful impact to patients worldwide.